Inhibition of cytotoxic T lymphocyte-induced target cell DNA fragmentation, but not lysis, by inhibitors of DNA topoisomerases I and II by unknown
Inhibition of Cytotoxic T Lymphocyte-induced Target 
Cell DNA Fragmentation,  but Not Lysis, by 
Inhibitors  of DNA Topoisomerases I and II 
By Walter K. Nishioka and Raymond M. Welsh 
From the Department of Pathology, University of Massachusetts Medical Center, Worcester, 
Massachusetts 01655 
Summary 
Cytotoxic T lymphocytes (CTL) kill their target cells via a contact-dependent mechanism that 
results in the perturbation  of the target cell's plasma membrane and the fragmentation  of the 
target cell's DNA into nucleosomal particles.  The membrane disruption is presumed to be due 
to the action of perforin,  while the DNA fragmentation  is thought  to be by the activation of 
an endogenous nuclease(s).  DNA topoisomerases I and II are nuclear enzymes with inherent 
endonuclease activities. We have investigated their role in the CTLinduced DNA fragmentation 
process. We report that in CTL killing assays, the treatment of target cells with topoisomerase 
I  and II inhibitors blocks the CTL-induced DNA fragmentation  process, but not the lysis of 
the target  cell. 
C 
TL deliver a lethal dose of granule-associated,  preformed 
cytotoxic components  onto  their  target  cell's plasma 
membrane (1-5). One component, perforin, inserts into the 
target's plasma membrane and forms nonspecific transmem- 
brane pores that presumably lead to the destruction of the 
target  by colloid  osmotic lysis  (1-3,  4).  In  addition,  the 
"lethally hit" targets undergo a suicide phenomenon known 
as apoptosis (1, 5, 6), principally characterized by the frag- 
mentation of the target's DNA (1-3, 6-9) into mono- and 
oligo-nucleosomal particles (7, 9,  10); single-strand lesions 
have also been found (11). The DNA fragmentation is thought 
to be mediated by the activation of a nuclease(s) endogenous 
to the target (1-3, 6-11). DNA topoisomerases are good can- 
didates to mediate these insults,  as the type I  (topo I) and 
type II (topo II) enzymes generate single- and double-strand 
breaks, respectively, in the DNA helix,  to relieve  torsional 
stress  in  the  cell's  chromatin  (12,  13).  Antitumor  agents 
that have been shown to specifically inhibit the activities of 
topo  I  (camptothecin)  and  topo II (4'-[9-acridinylamino]- 
methane-sulfon-m-anisidide  [mAMSA]  and  4'-demethyl- 
epipodophyllotoxin 4-[4,6,-O-thenylidene-13-D-glucopyrano- 
side]  [VM-26]) (14,  15) make it possible to study the role 
of these enzymes in CTbinduced  apoptosis. 
Materials  and Methods 
Generation and Preparation of Virus-specific CTL.  CTL were in- 
duced by the injection of 6-12-wk-old male or female (C57BL/6 
x  C3H/HeSnJ)F~ mice with lymphocytic choriomeningitis virus 
(LCMV), ~ Armstrong strain (10). Single cell splenocyte prepara- 
t Abbreviation used in this paper: LCMV, lymphocytic choriomeningitis 
virus. 
tions, depleted of NK cell activity (10, 16), were prepared in warm 
(25-37~  RPMI 1640 (Gibco Laboratories, Grand Island, NY) 
containing  2% FCS (Sigma Chemical Co.,  St. Louis, MO) and 
25 mM Hepes (Sigma Chemical Co.), pH 7.4, and enriched for 
T cells (16, 17). Immediately before use, the T cells (CTL) were 
resuspended in RPMI 1640 containing 5% FCS (RPMI-5% FCS). 
Cytotaxia'ty Assays.  mCr (Amersham Corp., Arlington Heights, 
IL) and [12sI]IUDR (ICN Radiochemicals, Irvine, CA) (t~I-DNA) 
release assays were performed  in  parallel (10). For  SlCr release 
assays, L-929 cells were labeled with SlCr in RPMI-5% FCS (10). 
To 12 x  75-mm glass tubes (Fisher Scientific, Pittsburgh,  PA) was 
added 10/zl of the desired topoisomerase inhibitor  (100  x  concen- 
tration), dissolved  in DMSO (Flu/ca Chemical Corp., Ronkonkoma, 
NY), at two times its final concentration  in the assay. 1 ml of 
S~Cr-labeled targets (10  s cells per ml) containing  5 #g/ml of Con 
A (Sigma Chemical Co.) was added to these tubes. DMSO alone 
did not inhibit effector cell activity or cause spontaneous cell death 
by SlCr or t~I-DNA release (data not shown).  The target  cells 
were aliquoted into 96-well plates (Costar, Cambridge, MA) at 104 
targets per well in 100/zl and allowed to stand at room tempera- 
ture (25~  for 1-1.5 h, and the effector cells were added in 100 
#1, in quadruplicate wells, for a final E/T ratio of 50:1. To parallel 
wells, RPMI-5% FCS was added, to serve as spontaneous release 
controls  for each dose of drug.  All wells contained Con A at a 
final concentration  of 2.5 #g/ml. Spontaneous SlCr release from 
these samples was usually <5% above the spontaneous release of 
those samples that did not contain any inhibitors (data not shown). 
The E/T cell mixture was incubated at 37~  5% COz, and the 
medium was collected for counting after 6-10 h. For the 12SI-DNA 
targets, 10/zl of the inhibitor  in DMSO was added to each assay 
tube (Sarstedt, Newton, NC) at two times its final concentration. 
I ml (10  s cells/ml) of target cells containing Con A (5 #g/ml) was 
added and the mixture was incubated for 1-1.5 h at room tempera- 
ture.  1 ml of effector cells was added to achieve a final E/T ratio 
of 50:1 and a final Con A concentration  of 2.5/zg/ml.  The cell 
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Figure 1.  Target  cell  lysis  and sohbilized  DNA release 
induced by LCMV-induced  CTL in the presence and ab- 
sence of topoisomerase  I and II inhibitors. (A) Treatment 
of target ceils with the topoisomerase I inhibitor  camp- 
tothecin; (B) treatment of target ceils with the topo- 
isomerase  II inhibitor  mAMSA;  (C) combined  treatment 
of target ceils  with camptothecin  and mAMSA;  (D) treat- 
ment of target ceils with the nonintercalating topo- 
isomerase II inhibitor VM-26. slCr release (O)  and 
nSI-DNA release (O) in the presence of varying  concen- 
trations of drug in/~M. All samples  were at an E/T ratio 
of 50:1. Camptothecin  lactone  (NSC-94600) and mAMSA 
(NSC-249992) were obtained from the Drug Synthesis 
and Chemistry  Branch, Division of Cancer Treatment, 
National Cancer Institute, Bethesda, MD. 
mixture was incubated at 37~  5% CO2 for 6-10 h. After the 
desired incubation period, the samples were pelleted at 500 g. The 
media from the tubes were collected, and the percent specific 12~I- 
DNA release was calculated (10). The 12SI-DNA release portion 
of the assay  was performed with samples in triplicate. The sponta- 
neous release of 125I-DNA from target cells incubated in the pres- 
ence of the highest concentration of inhibitor was always <5% 
of the release from the targets without the inhibitor  (data not 
shown). 
DNA  Isolation and Electrophoresis.  All 12SI-DNA cell pellets 
were pre-treated with 0.5 ml "topo lysis"  buffer (18-20) containing 
20 mM Tris (Research Organics, Cleveland, OH), pH 7.4, 0.15 
M NaCI (Fisher ,Scientific  Co.), 1% NP-40 (Sigma Chemical Co.), 
and 20 mM EDTA (Research Organics) for 10--30 rain at 37~ 
Total sample DNA was purified as described (21) with modificat- 
ions. After topo lysis buffer treatment, an equal volume of a 9 M 
guanidine HC1 (United States Biomedical  Corp., Cleveland, OH, 
and Research Organics) solution containing 20 mM Tris, pH 8.0, 
5 mM EDTA, was added to denature ceUular proteins and to in- 
hibit further nuclease  activities, for a final concentration of 4.5 M. 
The samples, in guanidine  HCL, were counted on a gamma counter 
(5500; Beckman  Instruments, Inc., Palo Alto, CA). After counting 
to determine the levels of 12SI-DNA release, the respective samples, 
in triplicate, were pooled and incubated at 37~  overnight. The 
pooled samples were then extracted once or twice with chloro- 
form/isoamyl  alcohol  at 24:1 (Fisher Scientific  Co.), and the aqueous 
phase was mixed with an equal vohme of isopropanol (Fisher 
Scientific Co.). The DNA was precipitated overnight at  -20~ 
and isohted by centrifugation at 12,000 g. The purified nSI-DNA 
was subjected to electrophoresis in a 1.5% agarose gd (Bio-Rad 
Laboratories, Richmond, CA), and the gd was processed for auto- 
radiography as previously described (10). 
Rationale.for DNA Processing Method.  Topoisomerase  targeting 
drugs trap their respective topoisomerase in an enzyme-bridged 
strand-break intermediate, termed the "cleavable complex" (15). 
Exposure of the cleavable complex to SDS or alkali denatures the 
topoisomerase-DNA interaction such that a DNA strand-break 
occurs by  virtue  of the  release of one  DNA  terminus;  the 
topoisomerase remains covalently linked to the other terminus of 
the broken strand (15, 20). Treatment of the DNA with EDTA 
(>1 mM) (18, 19), high salt (0.5 M) (19), or high heat (>55~ 
(20) induces the dissohtion of the cleavable complex and allows 
the religation reaction of the cleaved  DNA termini to occur. Thus, 
exposure of  the drug-treated samples with the topo lysis  buffer con- 
taining 20 mM EDTA, before  DNA purification  with the chaotropic 
agent, guanidine  hydrochloride,  prevents  drug-induced  DNA strand- 
break artifacts. 
Results  and  Discussion 
Camptothecin, mAMSA, and VM-26 are cytotoxic to all 
cycling cells (15). Their toxicity is directly proportional to 
the rate of cell proliferation (22). Drug titration assays were 
performed to determine the highest tolerable concentration 
of each drug, as assessed by spontaneous  SlCr release, for our 
target cells. We verified that cells grown in lower serum con- 
centrations, i.e.,  media containing 5%  FCS (5% FCS) vs. 
10% FCS, were less susceptible to drug-related cytotoxicity 
(22). Consequently, the target cells were cultured and assayed 
in 5% FCS. Initial analysis of the killing of LCMV-infected 
targets in 5% FCS revealed, in comparison with 10% FCS, 
depressed levels of DNA fragmentation, but not SlCr release 
(data not shown). Preliminary data suggested that this was 
associated with a reduced proliferative  capacity of the virus- 
infected cells, probably due to viral interference of cellular 
metabolic pathways (23,  24),  which could be compensated 
for by high serum concentrations (data not shown). To test 
the ef~cacy of the drugs in 5% FCS and under conditions 
free from the virus-induced interference in the target cell's 
metabolism, we used uninfected L-929 cells as targets with 
LCMV-induced CTL in a lectin-dependent  (25) killing system. 
The lectin Con A enables CTLs to nonspecifically bind and 
lyse uninfected target cells. 
To determine whether treatment with the topo I inhib- 
itor, camptothecin, would prevent CTbinduced DNA frag- 
mentation, [nsI]IUDR-labeled L-929 cells were preincubated 
with fivefold dilutions ofcamptothecin before CTL addition. 
24  DNA Topoisomerases in Cytotoxic  T Lymphocyte-induced  DNA Fragmentation A  parallel SlCr release cytotoxicity assay was performed to 
allow the comparison between cell lysis and DNA fragmen- 
tation. Fig. 1 A shows that camptothecin inhibited, in a dose- 
dependent manner, the CTL-induced DNA fragmentation 
in  the  L-929 target  cells,  assessed  by  [l~SI]IUDR-labeled 
DNA (12SI-DNA) release.  In contrast, SlCr release was not 
affected, indicating that the CTL were functional and could 
effect a perforin-like disruption (1, 4) of the target's plasma 
membrane. When the cell-associated  12SI-DNA was purified 
and subjected to electrophoresis (Fig.  2 A), the fragmenta- 
tion of target cell DNA into nucleosomal particles was in- 
hibited in a dose-dependent manner. As the concentration 
of camptothecin was decreased, an increasing proportion of 
DNA migrated as distinct bands, suggesting a processive mech- 
anism of degradation into nucleosome core particles.  Treat- 
ment with the topo II inhibitor,  mAMSA, yielded similar 
results.  Fig. 1 B shows that mAMSA treatment of target cells 
prevented ~zSI-DNA release, but not S~Cr release.  Fig.  2 B 
shows that the DNA fragmentation into nudeosomal parti- 
cles was also  inhibited,  similar to the inhibition by camp- 
tothecin (Fig.  2 B). 
When the inhibitors were combined, camptothecin and 
mAMSA caused effective inhibition of 12SI-DNA release at 
"~2.5-  and ,x,l.0-fold lower drug concentrations than that 
of either drug alone (Fig.  1 C). The autoradiogram (Fig.  2 
C)  of  the  electrophoresed  12SI-DNA samples  shows  an 
equivalent level of DNA fragmentation inhibition at a drug 
dose fivefold lower than either drug used alone. 
A property of mAMSA is that it intercalates into the DNA 
while binding to topo II (15). Perturbations in DNA struc- 
ture due to drug intercalation could affect the ability of the 
nudease(s) to recognize the DNA substrate (26, 27). We there- 
fore asked ffVM-26, a nonintercalating topo II inhibitor (15), 
could also block DNA fragmentation. VM-26, like the other 
inhibitors, blocked 12SI-DNA release (Fig.  1 D) and fragmen- 
tation  (Fig.  2  D),  but  not  SlCr  release  (Fig.  1 D).  Thus, 
Figure 2.  Autoradiograms  of electrophoresed  cell- 
associated 12SI-DNA samples from the experiments 
shown in Fig. 1 above. (A) Campwthecin-treated 
targets; (B) mAMSA-treatecl  targets; (C) combined 
treatment  of  targets  with camptothecin  and mAMSA; 
(D) samples  treated  with VM-26. Each  lane  was loaded 
with 30,000cpm _+ 5% ofsample.  Gelexposures  were 
done at  -70~  with two screens  for 72 h. 
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tion in the fragmentation of the target's DNA. 
To our knowledge, these results are the first to implicate 
distinct nuclear enzymes in the CTbinduced fragmentation 
of the target cell's DNA. We have also performed these ex- 
periments with the mouse mastocytoma cell line, P815, the 
prototype target for DNA fragmentation analysis, in short- 
term CTbmediated (2--4 h) and valinomycin-mediated  killing 
(28) assays (2 h), and have obtained results similar to those 
presented here (data not shown). 
Reported functions for topo I and II do not include exo- 
nuclease activities that could account for the processive diges- 
tion of the target's DNA into nudeosome core particles (12, 
13, 15). Topoisomerases act as swivels to relieve torsional con- 
straints acquired as a result of transcription, replication, and 
packaging of the cell's DNA (12, 13, 15). These superhdical 
motifs are a predicament for nuclear enzyme accessibility  to 
targeted DNA sequences (27, 29). Topoisomerases may thus 
play a supporting role by allowing the target cell's chromatin 
to  be  presented  as  a  more  accommodating substrate  for 
(exo)nuclease digestion. 
The experiments presented also shed light on the mecha- 
nism of target cell destruction induced by CTL. Proponents 
of the internal disintegration model (1-3, 6-8) of target cell 
killing by CTL have asserted that since the fragmentation 
of the target cell's  DNA occurs prelyticaUy,  i.e.,  [3H]thy- 
midine- or 12SI-DNA release can be measured from NP-40 
or Triton X-100 treated targets before the detectable release 
of 51Cr from these targets,  it is the fragmentation of the 
target cell's DNA that causes the disruption of the plasma 
membrane. Within our data, the fact that the significant reduc- 
tion in target cell DNA fragmentation is not followed by 
a corresponding inhibition of SlCr release suggests that the 
nuclear disintegration component of CTL-mediated killing 
may not be required for the disruption of the target cell's 
membrane and subsequent target cell death. In support of 
this, Zychlinsky et al.  (30)  have recently shown that zinc, 
an inhibitor of endogenous nudease activity (9), blocks DNA 
fragmentation, but not target cell lysis. Thus, the CTL,  induced 
membrane perturbation may be suf~cient for target cell death. 
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